GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procyon Corp (OTCPK:PCYN) » Definitions » Cash Conversion Cycle

PCYN (Procyon) Cash Conversion Cycle : 132.27 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Procyon Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Procyon's Days Sales Outstanding for the three months ended in Jun. 2024 was 32.13.
Procyon's Days Inventory for the three months ended in Jun. 2024 was 154.8.
Procyon's Days Payable for the three months ended in Jun. 2024 was 54.66.
Therefore, Procyon's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2024 was 132.27.


Procyon Cash Conversion Cycle Historical Data

The historical data trend for Procyon's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procyon Cash Conversion Cycle Chart

Procyon Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.32 170.42 169.60 172.33 137.89

Procyon Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.01 145.88 156.28 151.20 132.27

Competitive Comparison of Procyon's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procyon's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Procyon's Cash Conversion Cycle falls into.



Procyon Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Procyon's Cash Conversion Cycle for the fiscal year that ended in Jun. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=36.87+157.12-56.1
=137.89

Procyon's Cash Conversion Cycle for the quarter that ended in Jun. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=32.13+154.8-54.66
=132.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Procyon  (OTCPK:PCYN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Procyon Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Procyon's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Procyon Business Description

Traded in Other Exchanges
N/A
Address
164 Douglas Road, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
Executives
Foundation Speer 10 percent owner 2535 SUCCESS DRIVE, ODESSA FL 33556
Suggs Fred Wilson Jr director 60 FOREST LANE, GREENVILLE SC 29605
Steven Mccomas director 800 LASTAHOUSE DRIVE, VIDALIA GA 30474
Monica Mccullough director 1095 55TH TERR SO, SAINT PETERSBURG FL 33705
Joseph Raymond Treshler director PO BOX 5719, CLEARWATER FL 33758
George Otis Borak officer: Vice President 3300 COVE CAY DR, UNIT 7D, CLEARWATER FL 33760
Lynnda L Speer 10 percent owner 2535 SUCCESS DRIVE, ODESSA FL 33556
Richard M. Speer 10 percent owner 104 WOODMONT BOULEVARD, SUITE 415, NASHVILLE TN 37205
Speer Roy M Foundation 10 percent owner 2535 SUCCESS DRIVE, ODESSA FL 33556
Paul Edward Kudelko director 28 WINSTON DR, BELLEAIR FL 33756
Justice Wolfe Anderson director, officer: VP-Sales and Marketing 1300 S HIGHLAND AVE, CLEARWATER FL 33756
Regina Wolfe Anderson director 1300 S HIGHLAND AVE, CLEARWATER FL 33756
Jeffrey S Slowgrove director C/O INFORMATION MANAGEMENT RESOURCES INC, 26750 US HIGHWAY N #500, CLEARWATER FL 34621
John C Anderson Trust 10 percent owner 440 S GULFVIEW BLVD, APT 1702N, CLEARWATER FL 33767
Michael Timothy Foley director 2284 KINGS POINT DRIVE, LARGO FL 33774

Procyon Headlines

No Headlines